Drug intelligence / Profile preview

azathioprine + cyclosporine + mycophenolate mofetil

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This combination is used for immunosuppression, primarily in organ transplantation. **Azathioprine** is an anti-proliferative drug that inhibits DNA synthesis by interfering with purine metabolism. **Cyclosporine** is a calcineurin inhibitor that suppresses T-cell activation. **Mycophenolate mofetil** inhibits inosine monophosphate dehydrogenase (IMPDH), reducing lymphocyte proliferation. Together, they enhance graft survival by reducing immune responses.

Targets

CN (Calcineurin)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)PPIA (Peptidyl-prolyl cis-trans isomerase A)

Beyond the preview

Go deeper on azathioprine + cyclosporine + mycophenolate mofetil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azathioprine + cyclosporine + mycophenolate mofetil.

Explore the full profile